Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the ...

The incidence of obesity and diabetes is rising in India, the world’s most populous country, which also ranks among the worst ...

India is stepping into the billion-dollar weight-loss drug war! With Wegovy and Mounjaro already here, Biocon is quietly ...

Hims & Hers, the high-flying online health company that rapidly grew from a buzzy startup selling Viagra to a multibillion-dollar business, had a hard month.

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Popular weight loss drugs like Ozempic and Mounjaro are now linked to rare but serious cases of acute pancreatitis, including ...

Sales of Eli Lilly’s Mounjaro double in a month; Novo Nordisk’s Wegovy enters market amid rising obesity and diabetes rates.

A NEW study challenges the idea that weight loss jabs decrease muscle mass, alongside fat. Scientists say one injection – ...

CVS Caremark has removed coverage of Zepbound, a GLP-1 weight-loss drug, citing pricing concerns and shifting payer dynamics ...

Demand for weight-loss drugs is rising at a fast clip in India where rivals Eli Lilly and Novo Nordisk are competing for ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?